Sagimet Biosciences (SGMT) Operating Leases (2022)

Sagimet Biosciences' (SGMT) quarterly Operating Leases came in at $78000.0 in Q4 2022.

Sagimet Biosciences (SGMT) Operating Leases (2022) Analysis & Trends

Sagimet Biosciences' Operating Leases history runs 1 years deep, the most recent figure standing at $78000.0 for Q4 2022.

  • On a quarterly basis, Operating Leases changed N/A year-over-year to $78000.0 in Q4 2022; TTM through Dec 2022 was $78000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $78000.0, changed N/A from the prior year.
  • Operating Leases steadied at $78000.0 in Q4 2022 per SGMT's latest filing.
  • Across five years, Operating Leases topped out at $78000.0 in Q4 2022 and bottomed at $78000.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Sagimet Biosciences 227.27 Mn 227.27 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 78,000.00